Jessica Shiu

Jessica Shiu

Auto-generated profile, based on publicly available information

Jessica Shiu

Department of Dermatology, University of California, Irvine, California

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 November 2015 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
LWLinghua Wang
Linghua Wang
XNXiao Ni
Xiao Ni
KCKyle R Covington
Kyle R Covington
BYBetty Y Yang
Betty Y Yang
JSJessica Shiu
Jessica Shiu
Madeleine DuvicMadeleine Duvic
Madeleine Duvic

8 July 2022 in JCI Insight
Verified
Journal Article
Open access
PDF file
JSJessica Shiu
Jessica Shiu
LZLihua Zhang
Lihua Zhang
GLGriffin Lentsch
Griffin Lentsch
JFJessica L. Flesher
Jessica L. Flesher
SJSuoqin Jin
Suoqin Jin
AGAnand K. Ganesan
Anand K. Ganesan
Vitiligo is an autoimmune skin disease characterized by the destruction of melanocytes by autoreactive CD8 + T cells. Melanocyte destruction in active vitiligo is mediated by CD8 + T cells, but the persistence of white patches in stable disease is poorly understood. The interaction between immune cells, melanocytes, and keratinocytes in situ in human skin has been difficult to study due to the lack of proper tools. We combine noninvasive multiphoton microscopy (MPM) imaging and single-cell RNA-Seq (scRNA-Seq) to identify subpopulations of keratinocytes in stable vitiligo patients. We show that, compared with nonlesional skin, some keratinocyte subpopulations are enriched in lesional vitiligo skin and shift their energy utilization toward oxidative phosphorylation. Systematic investigation of cell-to-cell communication networks show that this small population of keratinocyte secrete CXCL9 and CXCL10 to potentially drive vitiligo persistence. Pseudotemporal dynamics analyses predict an alternative differentiation trajectory that generates this new population of keratinocytes in vitiligo skin. Further MPM imaging of patients undergoing punch grafting treatment showed that keratinocytes favoring oxidative phosphorylation persist in nonresponders but normalize in responders. In summary, we couple advanced imaging with transcriptomics and bioinformatics to discover cell-to-cell communication networks and keratinocyte cell states that can perpetuate inflammation and prevent repigmentation.

1 February 2020 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
FCFranchesca D. Choi
Franchesca D. Choi
CKChristina N. Kraus
Christina N. Kraus
AEAshley N. Elsensohn
Ashley N. Elsensohn
SCSama K. Carley
Sama K. Carley
LLLarisa M. Lehmer
Larisa M. Lehmer
JSJessica Shiu
Jessica Shiu

22 January 2013 in Pathogens and Disease
Verified
Journal Article
Closed access
PDF file
JSJessica Shiu
Jessica Shiu
TBThomas G. Blanchard
Thomas G. Blanchard

13 October 2020 in eLife
Verified
Journal Article
Open access
RRRolando Ruiz-Vega
Rolando Ruiz-Vega
CCChi-Fen Chen
Chi-Fen Chen
EREmaad Razzak
Emaad Razzak
PVPriya Vasudeva
Priya Vasudeva
TKTatiana B Krasieva
Tatiana B Krasieva
ALArthur D Lander
Arthur D Lander
Mutational activation of the BRAF proto-oncogene in melanocytes reliably produces benign nevi (pigmented ‘moles’), yet the same change is the most common driver mutation in melanoma. The reason nevi stop growing, and do not progress to melanoma, is widely attributed to a cell-autonomous process of ‘oncogene-induced senescence’. Using a mouse model of Braf-driven nevus formation, analyzing both proliferative dynamics and single-cell gene expression, we found no evidence that nevus cells are senescent, either compared with other skin cells, or other melanocytes. We also found that nevus size distributions could not be fit by any simple cell-autonomous model of growth arrest, yet were easily fit by models based on collective cell behavior, for example in which arresting cells release an arrest-promoting factor. We suggest that nevus growth arrest is more likely related to the cell interactions that mediate size control in normal tissues, than to any cell-autonomous, ‘oncogene-induced’ program of senescence.

11 July 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
HDHua Ding
Hua Ding
JNJohn G. Nedrud
John G. Nedrud
TBThomas G. Blanchard
Thomas G. Blanchard
BZBrandon M. Zagorski
Brandon M. Zagorski
GLGuanghui Li
Guanghui Li
SCSteven J. Czinn
Steven J. Czinn
Helicobacter pylori (H. pylori) infection can be significantly reduced by immunization in mice. Th17 cells play an essential role in the protective immune response. Th1 immunity has also been demonstrated to play a role in the protective immune response and can compensate in the absence of IL-17. To further address the potential of Th1 immunity, we investigated the efficacy of immunization in mice deficient in IL-23p19, a cytokine that promotes Th17 cell development. We also examined the course of Helicobacter infection in unimmunized mice treated with Th1 promoting cytokine IL-12. C57BL/6, IL-12 p35 KO, and IL-23 p19 KO mice were immunized and challenged with H. pylori. Protective immunity was evaluated by CFU determination and QPCR on gastric biopsies. Gastric and splenic IL-17 and IFNγ levels were determined by PCR or by ELISA. Balb/c mice were infected with H. felis and treated with IL-12 therapy and the resulting gastric bacterial load and inflammatory response were assessed by histologic evaluation. Vaccine induced reductions in bacterial load that were comparable to wild type mice were observed in both IL-12 p35 and IL-23 p19 KO mice. In the absence of IL-23 p19, IL-17 levels remained low but IFNγ levels increased significantly in both immunized challenged and unimmunized/challenged mice. Additionally, treatment of H. felis-infected Balb/c mice with IL-12 resulted in increased gastric inflammation and the eradication of bacteria in most mice. These data suggest that Th1 immunity can compensate for the lack of IL-23 mediated Th17 responses, and that protective Th1 immunity can be induced in the absence of immunization through cytokine therapy of the infected host.